Antiretroviral therapy and cardiovascular risk: Are some medications cardioprotective?

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 226-233

  Eckhardt, Benjamin J ^a   Glesby, Marshall J ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiretroviral therapy; Coronary heart disease; Glucose homeostasis; Lipids

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TORCETRAPIB; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFECT; DRUG SUBSTITUTION; GLUCOSE HOMEOSTASIS; HEART PROTECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME;

EID: 42049093794     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f6451a     Document Type: Review

References (70)

1. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
2. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunode-ficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512.
3. Klein D, Hurley L, Silverberg M, et al. S. Surveillance date for myocardial infarction hospitalizations among HIV(+) and HIV(-) Northern Californians: 1994-2006. Poster presentation at 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Poster 807.
4. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
5. Friis-Moller N, Reiss P, Sabin C, Weber R, et al., The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. An important observational study that shows the most convincing evidence for the link between exposure to antiretroviral medication, specifically protease inhibitor-based regimens, and the incidence of myocardial infarction. Use of nonnucleoside reverse transcriptase inhibitor-based regimens was not associated with increased risk of myocardial infarction.
6. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
7. Rose H, Wooley I, Hoy J, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of the treatment. Metabolism Clinical and Experimental 2006; 55:90-95.
8. Riddler S, Smit E, Cole S, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
9. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999; 100:700-705.
10. Mulligan K, Grunfeld C, Tai V, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
11. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and postherparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
12. Lee G, Seneviratne T, Noor M, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18:641-649.
13. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
14. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomized noninferority trail. Lancet 2006; 368:476-482.
15. Smith K, Weinberg W, DeJesus E, et al. Once-daily ritonavir (100 mg) boosting of fosamprenavir (FPV/r) or atazanavir (ATZ/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naïve HIV-infected patients: 48-week safety/efficacy results from COL103952(ALERT). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney. Abstract WEPEB023.
16. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and Safety of darunavir/ritonavir vs. lopinavir/ritonavir in ARV treatment-naïve HIV-1-infected patients at Week 48: ARTEMIS. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Abstract H-718b.
17. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentration. HIV Med 2005; 6:421-425.
18. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994; 121:641-647.
19. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. J Acquir Immune Defic Syndr 2007; 47:161-167. This paper demonstrates the modest impact of ritonavir-boosting on lipids in atazanavir-based regimens.
20. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS 2003; 17:2603-2614.
21. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005; 39:174-180.
22. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711-718.
23. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS 2001; 15:2407-2417.
24. Negredo E, Ribalta J, Ferre R, et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004; 18:819-821.
25. Dube M, Parker R, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-1818.
26. Pereira S, Branco T, Corte-Real R, et al. Long-term and concentration-dependent beneficial effects of efavirenz on HDL-cholesterol in HIV-infected patients. Br J Clin Pharmacol 2006; 61:601-604.
27. Shikuma C, Yang Y, Glesby M, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007; 44:540-550. This study demonstrates modest effects of efavirenz-based regimens and triple nucleoside reverse transcriptase inhibitors on glucose homeostasis and lipids. Relative to US population-based data, the HIV-infected patients had higher triglycerides and lower HDL-C after 96 weeks of treatment.
28. van Leth F, Phanuphak P, Stores E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med 2004; 1:e19.
29. Barter P, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
30. van Leth F, Hall DB, Lange JM, Reiss P. Plasma lipid concentration after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med 2006; 7:347-350.
31. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34:504-510.
32. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19:917-925.
33. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6:396-402.
34. Lafeuillade A, Jolly P, Chadapaud S, et al. Evolution of lipid abnormalities in patients switched from stavudine-to-tenofovir-containing regimens. J Acquir Immune Defic Syndr 2003; 33:544-546.
35. Gallant J, Staszewski S, Pozniak A, DeJesus E, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA 2004; 292:191-201.
36. Llibre J, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20:1407-1414.
37. Squires K, Pozniak A, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-320.
38. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
39. Saag M, Ive P, Heere J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc vs efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for treatment of antiretroviral naïve patients infected with R5 HIV 1: week 48 results of the MERIT study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney. Abstract WESS104.
40. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infections. J Acquir Immune Defic Syndr 2007; 46:125-133. This study demonstrates the lack of effect of raltegravir on lipids in treatment naïve patients.
41. Walli R, Herfort O, Michl G, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12:F167-F173.
42. Behrens G, Ddejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-F70.
43. Brown T, Cole S, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005; 165:1179-1184.
44. Tien P, Schneider M, Cole S, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21:1739-1745.
45. Noor M, Seneviratne T, Aweeka F, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
46. Lee G, Lo J, Aweeka F, et al. Single-dose lopinavir-ritonavir acuely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660.
47. Noor M, Lo J, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:11-18.
48. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6:13-21.
49. Addy C, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-636.
50. Lee G, Mafong D, Noor M, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
51. Noor M, Parker R, O'Mara E, et al. The effect of HIV protease inhibitor atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144.
52. Noor M, Flint O, Maa JF, Parker R. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
53. Brown T, Li X, Cole S, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors in associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383.
54. Fleischman A, Johnson S, Systrom D, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2006; 292:E1666-E1673.
55. Martinez E, Arnaiz J, Podzamczar D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
56. Jemsek J, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naïve HIV-infected patients. Clin Infect Dis 2006; 42:273-280.
57. Johnsen S, Dolan S, Fitch K, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006; 91:4916-4923.
58. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25:312-321.
59. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640-1649.
60. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139.
61. Stein J, Klein M, Bellehumeur J, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
62. Torriani F, Komarow L, Cotter B, et al. Control of HIV viral replication is associated with rapid improvement in endothelial function sustained over twenty-four weeks: A5152s, a substudy of A5142. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney. Abstract WEAB302.
63. El-Sadr WM, Lundgren JD, Neaton JD, et al., The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
64. Tebas P, Henry K, Matining R, et al. Antiretroviral treatment interruption, immune activation and cardiovascular risk. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago. Abstract H-378.
65. Phillips A, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles. Oral Abstract 41.
66. Balotta C, Bagnarelli P, Violin M, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997; 11:F67-F71.
67. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 315:14-18.
68. Gonzalaz P, Alvarez R, Batalla A, et al. Genetic variation in the chemokine receptor CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2:191-195.
69. van Wanrooij E, Happe H, Hauer A, et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25:2642-2647.
70. FDA. Selzentry Prescribing Information [updated 8/02/07]. Available at http://www.fda.gov/cder/foi/label/2007/0221281.lbl.pdf.